<DOC>
	<DOCNO>NCT01981109</DOCNO>
	<brief_summary>The primary purpose research describe patient characteristic predictive imaging study positive distant metastasis patient castration-resistant prostate cancer know distant metastasis .</brief_summary>
	<brief_title>A Study Evaluate Characteristics Predictive Positive Imaging Study Distant Metastases Patients With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Written inform consent obtain prior initiation study procedure . Men ≥ 18 year age . Histologically document prostatic adenocarcinoma . History CastrationResistant Prostate Cancer . Known M1 disease . Undergone image study metastatic prostate cancer ≤ 3 month . ECOG performance status ≥ 3 . Known malignant pleural effusion ascites . Current prior treatment investigational therapy M0 CastrationResistant Prostate Cancer ( Taxotere ( docetaxel ) , Provenge® ( sipuleucelT ) , Zytiga ( abiraterone acetate ) , Xtandi ( enzalutamide ) , Jevtana ( cabazitaxel ) , Xofigo ( radium Ra 223 dichloride ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>